Bolt Biotherapeutics
BOLT
24 hedge funds and large institutions have $4.28M invested in Bolt Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 4 closing their positions.
4% less funds holding
Funds holding: 25 → 24 (-1)
4.41% less ownership
Funds ownership: 46.3% → 41.89% (-4.4%)
16% less capital invested
Capital invested by funds: $5.1M → $4.28M (-$819K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$92.3K |
| 2 |
SC
Shay Capital
New York
|
+$88.5K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
+$68.3K |
| 4 |
Renaissance Technologies
New York
|
+$57.1K |
| 5 |
Squarepoint
New York
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$554K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$134K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$62.4K |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$20.1K |
| 5 |
BlackRock
New York
|
-$4.65K |
BOLT Hedge Fund Activity: Q3 2025 in Review
24 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2025, worth a combined $4.28M — down 16% from $5.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BOLT and 3 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $92.3K. The largest seller was Tang Capital Management, cutting an estimated $554K.
- 24 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2025, down from 25 in Q2 2025.
- Funds reported $4.28M of Bolt Biotherapeutics stock for Q3 2025, down 16% quarter-over-quarter.
- 3 funds opened new Bolt Biotherapeutics positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest Bolt Biotherapeutics buyer in Q3 2025 was Susquehanna International Group, an estimated $92.3K added.
- The largest Bolt Biotherapeutics seller in Q3 2025 was Tang Capital Management, an estimated $554K sold.
Based on aggregated 13F filings for Q3 2025.